189 related articles for article (PubMed ID: 35837305)
1. Predicting Progression, Recurrence, and Survival in Pancreatic Neuroendocrine Tumors: A Single Center Analysis of 174 Patients.
Krogh S; Grønbæk H; Knudsen AR; Kissmeyer-Nielsen P; Hummelshøj NE; Dam G
Front Endocrinol (Lausanne); 2022; 13():925632. PubMed ID: 35837305
[TBL] [Abstract][Full Text] [Related]
2. A preoperative computed tomography radiomics model to predict disease-free survival in patients with pancreatic neuroendocrine tumors.
Homps M; Soyer P; Coriat R; Dermine S; Pellat A; Fuks D; Marchese U; Terris B; Groussin L; Dohan A; Barat M
Eur J Endocrinol; 2023 Oct; 189(4):476-484. PubMed ID: 37787635
[TBL] [Abstract][Full Text] [Related]
3. A single-center experience with pancreatic cystic neuroendocrine tumors.
Khalil A; Ewald J; Marchese U; Autret A; Garnier J; Niccoli P; Piana G; Poizat F; Giovannini M; Delpero JR; Turrini O
World J Surg Oncol; 2020 Aug; 18(1):208. PubMed ID: 32799893
[TBL] [Abstract][Full Text] [Related]
4. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
[TBL] [Abstract][Full Text] [Related]
5. Impact of perioperative blood transfusion on survival in pancreatic neuroendocrine tumor patients: analysis from the US Neuroendocrine Study Group.
Marincola Smith P; Baechle J; Solórzano CC; Tan M; Lopez-Aguiar AG; Dillhoff M; Beal E; Poultsides G; Cannon JGD; Rocha FG; Crown A; Cho C; Beems M; Winslow ER; Rendell VR; Krasnick BA; Fields RC; Maithel SK; Bailey CE; Idrees K
HPB (Oxford); 2020 Jul; 22(7):1042-1050. PubMed ID: 31806388
[TBL] [Abstract][Full Text] [Related]
6. International Validation of a Nomogram to Predict Recurrence after Resection of Grade 1 and 2 Nonfunctioning Pancreatic Neuroendocrine Tumors.
Heidsma CM; van Roessel S; van Dieren S; Engelsman AF; Strobel O; Buechler MW; Schimmack S; Perinel J; Adham M; Deshpande V; Kjaer J; Norlen O; Gill AJ; Samra JS; Mittal A; Hoogwater FJH; Primavesi F; Stättner S; Besselink MG; van Eijck CHJ; Nieveen van Dijkum EJM
Neuroendocrinology; 2022; 112(6):571-579. PubMed ID: 34343138
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET.
Lombardi M; De Lio N; Funel N; Sardella C; Russo D; Urbani C; Rossi G; Campani D; Martino E; Marcocci C; Boggi U; Bogazzi F
J Endocrinol Invest; 2015 Jun; 38(6):605-13. PubMed ID: 25501604
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of systemic immune-inflammation index in patients with nonfunction pancreatic neuroendocrine tumor undergoing surgical resection.
Chen G; Liu L; Tan C; Tan Q; Chen Y; An X; Liu X; Wang X
Cancer Med; 2024 Apr; 13(7):e7114. PubMed ID: 38553949
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Syndrome Is Associated with Impaired Survival after Surgery for Pancreatic Neuroendocrine Tumors.
Awwad F; Ozga AK; Amin T; Schlueter C; Kailani S; Perez D; Wolter S; Sauter G; Izbicki J; Lohse AW; Schrader J
Neuroendocrinology; 2022; 112(12):1225-1236. PubMed ID: 35354139
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in 151 patients with surgically resected non-functioning pancreatic neuroendocrine tumours.
Song KB; Kim SC; Kim JH; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
ANZ J Surg; 2016 Jul; 86(7-8):563-7. PubMed ID: 25040037
[TBL] [Abstract][Full Text] [Related]
11. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.
Fisher AV; Lopez-Aguiar AG; Rendell VR; Pokrzywa C; Rocha FG; Kanji ZS; Poultsides GA; Makris EA; Dillhoff ME; Beal EW; Fields RC; Panni RZ; Idrees K; Smith PM; Cho CS; Beems MV; Maithel SK; Winslow ER; Abbott DE; Weber SM
J Gastrointest Surg; 2019 Apr; 23(4):651-658. PubMed ID: 30659439
[TBL] [Abstract][Full Text] [Related]
12. Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place.
de Mestier L; Gaujoux S; Cros J; Hentic O; Vullierme MP; Couvelard A; Cadiot G; Sauvanet A; Ruszniewski P; Richard S; Hammel P
Ann Surg; 2015 Aug; 262(2):384-8. PubMed ID: 25185468
[TBL] [Abstract][Full Text] [Related]
13. Value of lymphadenectomy in patients with surgically resected pancreatic neuroendocrine tumors.
Zhang Z; Wang F; Li Z; Ye Z; Zhuo Q; Xu W; Liu W; Liu M; Fan G; Qin Y; Zhang Y; Chen X; Yu X; Xu X; Ji S
BMC Surg; 2022 May; 22(1):160. PubMed ID: 35538535
[TBL] [Abstract][Full Text] [Related]
14. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases.
Ye L; Ye H; Zhou Q; Li Z; Lin Q; Tan L; Gao W; Fu Z; Zheng S; Chen R
Int J Surg; 2016 May; 29():108-17. PubMed ID: 27000717
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
[TBL] [Abstract][Full Text] [Related]
16. Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior.
Morin E; Cheng S; Mete O; Serra S; Araujo PB; Temple S; Cleary S; Gallinger S; Greig PD; McGilvray I; Wei A; Asa SL; Ezzat S
Cancer Med; 2013 Oct; 2(5):701-11. PubMed ID: 24403235
[TBL] [Abstract][Full Text] [Related]
17. Patients with non-functional metastatic G2 pancreatic neuroendocrine tumor benefit from palliative surgery: A 20-year single-center retrospective analysis.
You T; Tang H; Xu X; Ying H; Sun Z; Cheng Y; Bai C
J Neuroendocrinol; 2022 Dec; 34(12):e13211. PubMed ID: 36373196
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of diagnosis, therapy and prognosis factors of 103 patients with pancreatic neuroendocrine tumors].
Luo Q; Liu YN; Ma HY; Li S; Huang JY; Li G; Jin G
Zhonghua Wai Ke Za Zhi; 2017 Oct; 55(10):755-759. PubMed ID: 29050176
[No Abstract] [Full Text] [Related]
20. Pancreastatin predicts survival in neuroendocrine tumors.
Sherman SK; Maxwell JE; O'Dorisio MS; O'Dorisio TM; Howe JR
Ann Surg Oncol; 2014 Sep; 21(9):2971-80. PubMed ID: 24752611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
